Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
Want to see MAZE full AI Analyst Report?
Top Page
Maze Therapeutics, Inc.
(NASDAQ:MAZE)
Select Model
Select Model
Rating:46Neutral
Price Target:
$23.00
▼(-18.12% Downside)
Action:Reiterated
Date:06/11/26
The score is held down primarily by weak financial performance (large losses and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events modestly offset this by improving funding/runway via the equity raise, while valuation is constrained by the negative P/E due to losses.
Positive Factors
Extended cash runway
The $150M registered offering materially extends liquidity and funds pivotal and Phase 2 programs into 2029, reducing near-term refinancing pressure. This durable runway supports multi-year clinical development timelines and strategic program advancement without immediate capital stress.
Negative Factors
Persistent cash burn
Sustained, large negative operating and free cash flow indicate the business remains dependent on external funding to support operations and trials. Over the medium term this heightens execution risk if clinical or partnership milestones slip and increases likelihood of future financings.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended cash runway
The $150M registered offering materially extends liquidity and funds pivotal and Phase 2 programs into 2029, reducing near-term refinancing pressure. This durable runway supports multi-year clinical development timelines and strategic program advancement without immediate capital stress.
Read all positive factors
Maze Therapeutics, Inc. (MAZE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.33B
Dividend YieldN/A
Average Volume (3M)506.24K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees125
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.75
Shares Outstanding55,345,260
10 Day Avg. Volume531,616
30 Day Avg. Volume506,239
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue66.34
Enterprise Value/Gross Profit72.08
Enterprise Value/Ebitda-11.10
Forecast
1Y Price Target
$63.56Price Target Upside126.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$20.00M
Maze Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Maze Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the creation of precise small molecule medications for a range of ailments within the United States. Its primary therapeutic targets encompass renal, car...
How the Company Makes Money
null...
Maze Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.00M | 0.00 | 167.50M | 0.00 | 0.00 |
| Gross Profit | 18.41M | -2.40M | 167.50M | 0.00 | 0.00 |
| EBITDA | -119.51M | -128.72M | 56.70M | -96.33M | -111.12M |
| Net Income | -122.54M | -131.12M | 52.23M | -100.42M | -114.94M |
Balance Sheet | |||||
| Total Assets | 419.71M | 397.13M | 240.54M | 71.50M | 149.96M |
| Cash, Cash Equivalents and Short-Term Investments | 352.38M | 341.92M | 196.81M | 29.16M | 99.92M |
| Total Debt | 61.22M | 23.31M | 26.63M | 49.62M | 32.05M |
| Total Liabilities | 78.01M | 42.16M | 43.64M | 61.45M | 48.51M |
| Stockholders Equity | 341.70M | 354.97M | 196.90M | 10.05M | 101.44M |
Cash Flow | |||||
| Free Cash Flow | -122.13M | -112.73M | 74.81M | -87.27M | -101.17M |
| Operating Cash Flow | -121.54M | -111.94M | 75.95M | -86.83M | -99.20M |
| Investing Cash Flow | -164.39M | -170.96M | -1.15M | -441.00K | -3.17M |
| Financing Cash Flow | 190.32M | 275.34M | 92.85M | 16.39M | 1.73M |
Maze Therapeutics, Inc. Risk Analysis
Maze Therapeutics, Inc. disclosed 83 risk factors in its most recent earnings report. Maze Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Maze Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $702.93M | 3.84 | 50.38% | ― | 384.60% | 883.51% | |
60 Neutral | $1.58B | -60.06 | 442.91% | ― | 107.73% | 82.33% | |
59 Neutral | $1.44B | -9.86 | -1057.44% | ― | ― | -13.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.66B | -11.71 | -44.10% | ― | 1205.52% | 81.79% | |
49 Neutral | $731.33M | -11.06 | -28.90% | ― | 68.64% | 50.57% | |
46 Neutral | $1.33B | -10.58 | -36.63% | ― | ― | ― |
* Healthcare Sector Average
MAZE
Maze Therapeutics, Inc.
24.05
10.65
79.48%
CRMD
Cormedix
8.74
-5.82
-39.97%
GERN
Geron
1.15
-0.36
-23.84%
KALV
KalVista Pharmaceuticals
27.00
14.04
108.33%
ANAB
AnaptysBio
56.07
40.53
260.72%
NUVB
Nuvation Bio
4.92
3.19
184.39%
Maze Therapeutics, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
Positive
Jun 10, 2026
On June 8, 2026, Maze Therapeutics, Inc. held its 2026 annual meeting of stockholders with 44,660,029 shares of common stock represented, or about 89.75% of shares entitled to vote, establishing a quorum for business. Stockholders voted on the ele...
Executive/Board Changes
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change
Neutral
May 22, 2026
On May 18, 2026, Maze Therapeutics, Inc. announced that Senior Vice President of Finance Amy Bachrodt had submitted her resignation, effective June 1, 2026, noting that her departure did not stem from any disagreement over the company’s oper...
Business Operations and StrategyPrivate Placements and Financing
Maze Therapeutics prices $150 million equity offering
Positive
Apr 22, 2026
On April 21, 2026, Maze Therapeutics, Inc. priced an underwritten registered offering of 5,540,000 shares of common stock at $23.50 per share and pre-funded warrants for 850,000 shares at $23.499, for expected gross proceeds of $150 million and es...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Maze Therapeutics adds Neil Kumar to board leadership
Positive
Mar 25, 2026
Maze Therapeutics reported fourth-quarter and full-year 2025 results on March 25, 2026, alongside positive Phase 2 HORIZON topline data for MZE829 showing clinically meaningful reductions in proteinuria in APOL1-mediated kidney disease, and confir...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.